share_log

翰森製藥:自願公告 -注射用HS-20110獲國家藥品監督管理局簽發的藥物臨床試驗批准通知書

HANSOH PHARMA: VOLUNTARY ANNOUNCEMENT -THE CLINICAL TRIAL APPROVAL FOR HS-20110 FOR INJECTIONISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

HKEX ·  Dec 17, 2024 20:43

Summary by Moomoo AI

翰森製藥集團有限公司於2024年12月16日宣佈,其自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110已獲中國國家藥品監督管理局(NMPA)簽發藥物臨床試驗批准通知書。該藥物擬開展用於晚期實體瘤的臨床試驗,標誌著公司在腫瘤治療領域的重要進展。此次獲批臨床試驗的HS-20110是翰森製藥在ADC領域的最新成果,反映了公司在創新藥物研發方面的持續投入。作為一種新型抗體–藥物偶聯物,HS-20110有望為晚期實體瘤患者提供新的治療選擇。此次臨床試驗批准將使翰森製藥能夠進一步評估HS-20110的安全性和有效性,為未來可能的藥物上市奠定基礎。
翰森製藥集團有限公司於2024年12月16日宣佈,其自主研發的新型抗體–藥物偶聯物(ADC)注射用HS-20110已獲中國國家藥品監督管理局(NMPA)簽發藥物臨床試驗批准通知書。該藥物擬開展用於晚期實體瘤的臨床試驗,標誌著公司在腫瘤治療領域的重要進展。此次獲批臨床試驗的HS-20110是翰森製藥在ADC領域的最新成果,反映了公司在創新藥物研發方面的持續投入。作為一種新型抗體–藥物偶聯物,HS-20110有望為晚期實體瘤患者提供新的治療選擇。此次臨床試驗批准將使翰森製藥能夠進一步評估HS-20110的安全性和有效性,為未來可能的藥物上市奠定基礎。
On December 16, 2024, HANSOH PHARMA announced that its independently developed new antibody-drug conjugate (ADC) injection HS-20110 has received the drug clinical trial approval notice from the National Medical Products Administration (NMPA) of China. The drug is intended for clinical trials in advanced solid tumors, marking an important advancement for the company in the field of cancer treatment.The approval of the clinical trial for HS-20110 is the latest achievement of HANSOH PHARMA in the ADC field, reflecting the company's ongoing investment in the development of Innovative Drugs. As a new antibody-drug conjugate, HS-20110 is expected to provide new treatment options for patients with advanced solid tumors. This clinical trial approval will enable HANSOH PHARMA to further assess the safety and efficacy of HS-20110, laying the foundation for the potential market launch of the drug in the future.
On December 16, 2024, HANSOH PHARMA announced that its independently developed new antibody-drug conjugate (ADC) injection HS-20110 has received the drug clinical trial approval notice from the National Medical Products Administration (NMPA) of China. The drug is intended for clinical trials in advanced solid tumors, marking an important advancement for the company in the field of cancer treatment.The approval of the clinical trial for HS-20110 is the latest achievement of HANSOH PHARMA in the ADC field, reflecting the company's ongoing investment in the development of Innovative Drugs. As a new antibody-drug conjugate, HS-20110 is expected to provide new treatment options for patients with advanced solid tumors. This clinical trial approval will enable HANSOH PHARMA to further assess the safety and efficacy of HS-20110, laying the foundation for the potential market launch of the drug in the future.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more